用 ivacaftor 治疗后便脂质组的变化,而没有微生物组或胆酸的变化
Rosara Bass1, Ceylan Tanes2, Kyle Bittinger2
1Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
概括
伊瓦卡夫托尔治疗没有改变囊性纤维化 (CF) 患者的肠道微生物群. 然而,它确实导致了便脂质概况的变化,特别是在胰腺不足和足够的CF组之间减弱了差异.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃肠道健康变化在囊性纤维化 (CF) 中很常见,并影响肺功能.
- 伊瓦卡夫托改善肺功能和体重,但其对肠道微生物群,脂质群和胆汁酸的影响不太清楚.
研究的目的:
- 调查 ivacaftor 对 CF 患者便微生物群,脂质群和胆酸概况的影响.
- 为了比较CF患者和健康的参考队列之间的这些个人资料.
主要方法:
- 分析了来自18名CF患者 (6-61岁) 和健康参考队列的便样本.
- 便微生物组,脂质组和胆酸度在基线和经过3个月的ivacaftor治疗后被评估.
主要成果:
- 与基线的健康人群相比,CF患者表现出不同的微生物群多样性; ivacaftor没有改变这一点.
- 七种便脂在 ivacaftor 治疗后增加,而胆酸度保持不变.
- 在胰腺不足 (PI-CF) 和胰腺充足 (PS-CF) 组之间,在脂质和胆酸概况中观察到显著差异,在基线观察到,并在治疗后减弱.
结论:
- 脏病患者的便微生物组与健康个体不同,并且在3个月的治疗后不会受到影响.
- 伊瓦卡夫托尔治疗导致便脂质组的适度变化.
- 在Ivacaftor治疗后,PI-CF和PS-CF亚组之间的脂质和胆酸概况的差异减少了.
相关概念视频
Lipid Absorption
495
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
495
Lipid Digestion
91.9K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
91.9K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
339
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
339
Drugs for Treatment of Constipation-Predominant IBS
183
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
183
Drugs for Treatment of Diarrhea-Predominant IBS
188
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
188
Drugs for Treatment of Ulcerative Colitis in IBD
152
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
152


